Should I Buy Insullet Corporation (PODD)? Finance YouTuber Analysis

The YouTuber identifies Insullet Corporation as a favorite in the healthcare sector, which is becoming a "very good deal" due to a gap between its price performance and strong fundamentals. The sector is expected to see 13% earnings growth and trades at or below its 10-year average P/E ratio, with analysts forecasting 15% returns.

“Favorites in the group include Insullet Corporation took her POD, Gilead Sciences, Gild and Device maker Medtronic took her MDT.”

The analyst highlights Insullet Corporation as a market leader in automated insulin devices with significant growth potential. Despite fears about GLP-1 weight loss drugs, the company's market position remains strong, and it continues to see over 20% annual sales growth. The stock is considered relatively cheap, with analysts projecting a substantial upside.

“Insulate sells the number one prescribed automated insulin device in the United States with over 250,000 users globally. And the total market for these devices is in the tens of millions. So we have insulate a market leader with lots of room to grow.”

The YouTuber recommends Insulet Corporation, noting its 25% gain since his previous recommendation, as it sells the leading automated insulin delivery device. Despite fears about weight-loss drugs, the company has a large addressable market, consistent 22% annual sales growth, and increasing profitability. Its current valuation is considered cheap, especially when adjusted for its 18.55% growth.

“Insulet sells the number one prescribed automated insulin delivery device in the United States with over 250,000 users globally the total market for these devices is in the tens of millions so we see an insulet a market leader with lots of room for growth.”

The YouTuber suggests Insulet Corporation, arguing that the sell-off due to fears about GLP-1 weight loss drugs impacting demand for insulin delivery systems is overdone. He believes medical device makers like Insulet could show surprising resilience in revenue.

“I think the sell-off is overdone though and a lot of these medical device makers like pod could see surprising resilience in Revenue.”

The analyst suggests Insulet as a potential rebound play, noting its focus on diabetic management through its Omnipod device and strong revenue growth. While acknowledging its high valuation and preferring Dexcom due to broader product offerings, he believes Insulet will perform well if GLP-1 drugs do not significantly impact the diabetes market.

“I think I prefer Dexcom here to insulate but both are going to do well if that glp1 drug fails to Dent that diabetes Market.”

While analysts forecast 20%+ sales growth and a high price target, the YouTuber notes the stock is quite expensive at about eight times price-to-sales. He questions the value, especially with potential weakness from the success of new diabetic and anti-obesity medications.

“this is still trading at about eight times price to sales ratio so I'm not sure the value is just there yet”

The YouTuber sees Insulet as a good entry opportunity despite recent pressure from weight-loss drugs, arguing the sell-off is overdone. They believe the company, as a market leader in insulin pump systems, offers a good long-term risk-reward profile, especially given its strong growth in the Omnipod system and potential for international expansion. The current P/E of 37 is considered fair for a market leader with growth potential, even if analysts' growth estimates are conservative.

“ich persönlich halte den Abverkauf nämlich für übertrieben und sehe hier eine gute Einstiegsmöglichkeit da das Unternehmen ein führendes Medizintechnikunternehmen in einer sehr interessanten Nische ist”